Готові списки джерел за темами / Differentiated thyroid cancers

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій
  6. Звіти організацій

Добірка наукової літератури з теми "Differentiated thyroid cancers"

Автор: Grafiati
Опубліковано: 7 грудня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Differentiated thyroid cancers".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Differentiated thyroid cancers"

1

Nix, P., A. Nicolaides, and A. P. Coatesworth. "Thyroid cancer review 2: management of differentiated thyroid cancers." International Journal of Clinical Practice 59, no. 12 (November 18, 2005): 1459–63. http://dx.doi.org/10.1111/j.1368-5031.2005.00672.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Krause, Kerstin, Stefan Karger, Oliver Gimm, Sien-Yi Sheu, Henning Dralle, Andrea Tannapfel, Kurt Werner Schmid, Corinne Dupuy, and Dagmar Fuhrer. "Characterisation of DEHAL1 expression in thyroid pathologies." European Journal of Endocrinology 156, no. 3 (March 2007): 295–301. http://dx.doi.org/10.1530/eje-06-0596.

Повний текст джерела
Анотація:
Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the recycling of iodide in the human thyroid. The aim of the present study was (I) to investigate whether DEHAL1 expression is different in differentially functioning thyroid pathologies and (II) to evaluate DEHAL1 as a possible marker of thyroid cell differentiation. Design and methods: Real-time PCR for DEHAL1 and its isoform DEHAL1B was performed in a series of 105 thyroid specimens, including toxic thyroid nodules (TTN), Graves’ disease (GD) thyroids, benign cold thyroid nodules (CTN), normal thyroid tissues and thyroid cancers (follicular thyroid carcinomas (FTC), papillary thyroid carcinomas (PTC), partially differentiated thyroid cancers (PDTC) and anaplastic thyroid carcinomas (ATC)). In addition, DEHAL1 protein expression was studied by immunohistochemistry in 163 benign and malignant thyroid pathologies and normal thyroids. Results: (I) The highest DEHAL1 mRNA levels were found in GD thyroids, while downregulation of DEHAL1 and DEHAL1B mRNA occurred in PTC and ATC (P<0.001 and <0.05 respectively); (II) DEHAL1 protein was overexpressed in TTNs and GD thyroids with predominant apical staining in all samples; (III) a weaker and patchy staining pattern was found in CTNs and normal thyroids; (IV) in differentiated thyroid cancers (FTC and PTC), a diffuse cytoplasmic DEHAL1 expression was found; and (V) in PDTC and ATC, DEHAL1 expression was faint or absent. Conclusion: Upregulation of DEHAL1 protein expression and sublocalisation of DEHAL1 at the apical cell pole in TTNs and GD thyroids is consistent with increased thyroid hormone turnover during thyrotoxicosis. Diffuse cytoplasmatic localisation or downregulation of DEHAL1 expression in thyroid cancers suggests alteration or loss of DEHAL1 function during thyroid cell dedifferentiation.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Iftikhar, Haissan, Mubasher Ikram, Adnan Muhammad, and Karim Nathani. "Unusual Presentation of Differentiated Thyroid Cancer Metastasis." International Archives of Otorhinolaryngology 22, no. 02 (July 14, 2017): 167–70. http://dx.doi.org/10.1055/s-0037-1604038.

Повний текст джерела
Анотація:
Introduction The rates of thyroid cancers are on a rise, especially well-differentiated thyroid cancers. This could be partly due to newer diagnostic modalities, like high-resolution ultrasound, that can pick up smaller lesions. Differentiated thyroid cancers with distant metastases are not common, and even rarer is the initial presentation with complaints not related to the neck. Objectives The objective of this series was to study and report the unusual cases of patients with differentiated thyroid cancer with distant metastasis. There is a lack of data in the literature on these cases, and due to the rarity of such metastases, no definite treatment protocol has been defined. Methods A retrospective chart review of 1,200 cases of thyroid surgeries was performed. A total of 10 cases of well-differentiated thyroid cancer on the final histopathology exam that had initially presented with usual complaints to departments other than the Otolaryngology Department were identified. Results A total of 6 patients had papillary carcinoma, whereas 4 patients had follicular carcinoma on final the histopathology exam. Two patients presented with iliac crest lesions, 2 with vertebral lesions one each with parapharyngeal mass, supraclavicular mass, labia majora swelling and bleeding, lung, rib and neck of femur lesion. Conclusion There are still no specific guidelines on how to address these patients with differentiated thyroid cancer with distant metastasis (except for the cases of bone and lung lesions) and on which treatment should be offered in case of recurrence. More studies on the subject are required.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Busaidy, Naifa Lamki, and Maria E. Cabanillas. "Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease." Journal of Thyroid Research 2012 (2012): 1–12. http://dx.doi.org/10.1155/2012/618985.

Повний текст джерела
Анотація:
Differentiated thyroid carcinoma (papillary and follicular) has a favorable prognosis with an 85% 10-year survival. The patients that recur often require surgery and further radioactive iodine to render them disease-free. Five percent of thyroid cancer patients, however, will eventually succumb to their disease. Metastatic thyroid cancer is treated with radioactive iodine if the metastases are radioiodine avid. Cytotoxic chemotherapies for advanced or metastatic noniodine avid thyroid cancers show no prolonged responses and in general have fallen out of favor. Novel targeted therapies have recently been discovered that have given rise to clinical trials for thyroid cancer. Newer aberrations in molecular pathways and oncogenic mutations in thyroid cancer together with the role of angiogenesis in tumor growth have been central to these discoveries. This paper will focus on the management and treatment of metastatic differentiated thyroid cancers that do not take up radioactive iodine.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Hartl, Dana M., Joanne Guerlain, Ingrid Breuskin, Julien Hadoux, Eric Baudin, Abir Al Ghuzlan, Marie Terroir-Cassou-Mounat, Livia Lamartina, and Sophie Leboulleux. "Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer." Cancers 12, no. 11 (November 6, 2020): 3282. http://dx.doi.org/10.3390/cancers12113282.

Повний текст джерела
Анотація:
Many recent publications and guidelines have promoted a “more is less” approach in terms of treatment for low to intermediate risk differentiated thyroid cancer (DTC), which comprise the vast majority of thyroid cancers: less extensive surgery, less radioactive iodine, less or no thyroid hormone suppression, and less frequent or stringent follow-up. Following this approach, thyroid lobectomy has been proposed as a means of decreasing short- and long-term postoperative morbidity while maintaining an excellent prognosis for tumors meeting specific macroscopic and microscopic criteria. This article will examine the pros and cons of thyroid lobectomy for low to intermediate risk cancers and discuss, in detail, criteria for patient selection and oncological outcomes.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Colevas, A. Dimitrios, and Manisha H. Shah. "Evaluation of Patients with Disseminated or Locoregionally Advanced Thyroid Cancer: A Primer for Medical Oncologists." American Society of Clinical Oncology Educational Book, no. 32 (June 2012): 384–88. http://dx.doi.org/10.14694/edbook_am.2012.32.30.

Повний текст джерела
Анотація:
Overview: Historically, patients with thyroid cancers are managed by endocrinologists, surgeons and radiation oncologists. Due to recent progress in this field with advances in treatment of thyroid cancer, medical oncologists are now commonly involved in care of patients with advanced thyroid cancers. In this manuscript, we describe general principles in management of patients with various types of thyroid cancers including differentiated, medullary and anaplastic thyroid cancers.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Suteau, Valentine, Mathilde Munier, Claire Briet, and Patrice Rodien. "Sex Bias in Differentiated Thyroid Cancer." International Journal of Molecular Sciences 22, no. 23 (November 30, 2021): 12992. http://dx.doi.org/10.3390/ijms222312992.

Повний текст джерела
Анотація:
Differentiated thyroid cancers are more frequent in women than in men. These different frequencies may depend on differences in patient’s behavior and in thyroid investigations. However, an impact on sexual hormones is likely, although this has been insufficiently elucidated. Estrogens may increase the production of mutagenic molecules in the thyroid cell and favor the proliferation and invasion of tumoral cells by regulating both the thyrocyte enzymatic machinery and the inflammatory process associated with tumor growth. On the other hand, the worse prognosis of thyroid cancer associated with the male gender is poorly explained.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Min, Seonyoung, and Hyunseok Kang. "What&apos;s New in Molecular Targeted Therapies for Thyroid Cancer?" Korean Society for Head and Neck Oncology 37, no. 2 (November 30, 2021): 1–9. http://dx.doi.org/10.21593/kjhno/2021.37.2.1.

Повний текст джерела
Анотація:
Thyroid cancer refers to various cancers arising from thyroid gland. Differentiated thyroid cancers (DTCs) include papillary, follicular, and Hurthle cell carcinomas and represent cancers retain normal thyroid functions such as iodine uptake. Radioactive iodine (RAI) is generally used for upfront treatment of metastatic DTCs, but RAI refractory DTCs remain to be clinical challenges. Sorafenib and lenvatinib were approved for the treatment of RAI refractory DTCs and more recently, genomics-based targeted therapies have been developed for NTRK and RET gene fusion-positive DTCs. Poorly differentiated and anaplastic thyroid cancers (ATCs) are extremely challenging diseases with aggressive courses. BRAF/MEK inhibition has been proven to be highly effective in BRAF V600E mutation-positive ATCs and immune checkpoint inhibitors have shown promising activities. Medullary thyroid cancers, which arise from parafollicular cells of thyroid, represent a unique subset of thyroid cancer and mainly driven by RET mutation. In addition to vandetanib and cabozantinib, highly specific RET inhibitors such as selpercatinib and pralsetinib have demonstrated impressive activity and are in clinical use.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Park, Jong-Lyul, Seon-Kyu Kim, Sora Jeon, Chan-Kwon Jung, and Yong-Sung Kim. "MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer." Cancers 13, no. 4 (February 5, 2021): 632. http://dx.doi.org/10.3390/cancers13040632.

Повний текст джерела
Анотація:
The challenge in managing thyroid nodules is to accurately diagnose the minority of those with malignancy. We aimed to identify diagnostic and prognostic miRNA markers for thyroid nodules. In a discovery cohort, we identified 20 candidate miRNAs to differentiate between noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) and papillary thyroid carcinomas (PTC) by using the high-throughput small RNA sequencing method. We then selected three miRNAs (miR-136, miR-21, and miR-127) that were differentially expressed between the PTC follicular variant and other variants in The Cancer Genome Atlas data. High expression of three miRNAs differentiated thyroid cancer from nonmalignant tumors, with an area under curve (AUC) of 0.76–0.81 in an independent cohort. In patients with differentiated thyroid cancer, the high-level expression of the three miRNAs was an independent indicator for both distant metastases and recurrent or persistent disease. In patients with PTC, a high expression of miRNAs was associated with an aggressive histologic variant, extrathyroidal extension, distant metastasis, or recurrent or persistent disease. Three miRNAs may be used as diagnostic markers for differentiating thyroid cancers from benign tumors and tumors with extremely low malignant potential (NIFTP), as well as prognostic markers for predicting the risk of recurrent/persistent disease for differentiated thyroid cancer.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Rao, Smitha S., and Sabaretnam Mayilvaganan. "Immuno-oncology of differentiated thyroid cancer." International Journal of Molecular & Immuno Oncology 6 (May 29, 2021): 72–75. http://dx.doi.org/10.25259/ijmio_36_2020.

Повний текст джерела
Анотація:
Thyroid cancer has become an epidemic due to easy availability of ultrasound of the neck, and in some countries, routine health checkup ultrasound of neck is routinely done and mandatory. Thyroid cancer detected incidentally and less than 1 cm may warrant only observation, whereas some cancers such as anaplastic thyroid cancer requires urgent intervention. Advances in the field of oncology have been revolutionized by the extensive study of tumor microenvironment (TME). The introduction of immune check point inhibitors resulted in a major shift in the understanding of differentiated thyroid cancer. Inflammation related to thyroid cancer involves various molecular patterns of cytokines and chemokines. They form the major targets for novel immunotherapies. Addition of discovery of newer tumor markers has significantly contributed to cancer management. Tumor immune escape is an important mechanism of oncogenesis. Innate immunity forms the major defense of the body to tumor cells. Polymorphonuclear leucocytes, macrophages, and lymphocytes form the defense that target tumor cells. The aim of this review is to comprehensively discuss the dynamic immune system, various oncogenic pathways and novel tumor antigens like cancer testis sperm associated antigen (SPAG9).
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Differentiated thyroid cancers"

1

Sheremet, M. I. "Differential diagnosis of nodular goiter on the background autoimmune thyroiditis and differentiated thyroid cancers." Thesis, БДМУ, 2022. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/19664.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Leboulleux, Sophie. "Place de l'iode 131 et de l'imagerie scintigraphique dans la prise en charge des cancers différenciés de la thyroïde." Thesis, Paris 11, 2013. http://www.theses.fr/2013PA11T062.

Повний текст джерела
Анотація:
Le traitement initial des cancers différenciés de la thyroïde (CTD) consiste en une thyroïdectomie totale suivie, dans de nombreux cas par l’administration d’iode 131. Après thyroïdectomie totale, un traitement par iode 131 est indiqué en fonction des caractéristiques tumorales initiales. Chez les patients à risque élevé de rechute il est recommandé d’administrer une forte activité d’iode 131. Chez les patients à très faible risque il est recommandé de ne pas administrer d’iode 131. Dans le groupe intermédiaire, il a été montré par deux études prospectives multicentriques randomisées (ESTIMABL et HILO) qu’une activité de 1,1 GBq (30 mCi) administrée après TSHrh (Thyroid Stimulating Hormon recombinante humaine) était adaptée. La désescalade thérapeutique se poursuit dans le cadre d’un autre essai prospectif randomisé (ESTIMABL 2) comparant une activité de 30 mCi après injection de TSHrh à une simple surveillance. Chez les patients avec maladie résiduelle la tomographie par émission de positon couplée à un scanner (TEP/TDM) au fluorodesoxyglucose (FDG) est un examen clé avec une valeur à la fois diagnostique et thérapeutique. Les fixations de FDG permettent de localiser la maladie résiduelle, surtout lorsqu’elle ne capte pas l’iode. Chez les patients dont le site de récidive n’est pas déterminé par l’échographie cervicale, la TEP/TDM au FDG est plus sensible que la scintigraphie post-thérapeutique réalisée après administration d’une forte activité d’iode 131 (dite activité empirique) et est considéré comme l’examen de première intention. La réalisation d’une stimulation par TSHrh avant la TEP au FDG augmente le nombre de lésions détectées et donc sa sensibilité sans que les modifications thérapeutiques qui en découlent soient néanmoins significatives. Le rôle de la TEP FDG dans la sélection des patients nécessitant un traitement par inhibiteur de tyrosine kinase et dans l’évaluation antitumorale des inhibiteurs de tyrosine kinase reste à démontrer. L’utilisation d’ITK pour ré-induire les fixations d’iode 131 sont une voie majeure de développement pour les patients ayant une maladie réfractaire à l’iode 131
Initial treatment of differentiated thyroid cancer is based on a total thyroidectomy and in many cases on the administration of radioactive iodine. Following total thyroidectomy, radioactive iodine is given, based on the primary tumor characteristics. In case of a very low risk of recurrence it is recommended not to give radioactive treatment. In case of high risk patients, a high activity of radioactive iodine is given after TSH stimulation. In case of intermediate risk patients, two randomized prospective studies (ESTIMABL and HILO) have shown that an activity of 1,1 GBq (30 mCi) given after rhTSH (recombinant human Thyroid Stimulating Hormon) was adequate. A further step is taken towards less treatment has now been undertaken with the ESTIMABL2 study, a prospective randomized study comparing a treatment with 1,1 GBq (30 mCi) of radioactive iodine treatment to follow-up without ablation. In patients with persistent disease, positron emission tomography with computed tomography (PET/CT) is a key examination used for its diagnostic and prognostic value. Foci of FDG uptake can localize residual disease, especially when it does not take up radioactive iodine. In patients in whom the site of recurrence remains unknown after a neck ultrasonography PET/CT with FDG is more sensitive than a post-therapeutic whole body scan performed after the administration of a high activity of radioactive iodine (empiric iodine) and should be considered as the first examination to perform. Injections of rhTSH before doing FDG PET/CT allow to increase the number of lesions detected, however the treatment changes linked to this preparation remains minor. The role of FDG PET/CT in the selection of patients to tyrosine kinase inhibitors (TKI) and to assess metabolic tumor response remains to be explored. The use of TKI to reinduce radioactive iodine uptake is a major research subject for patients with radioactive iodine refractory disease
Стилі APA, Harvard, Vancouver, ISO та ін.
3

D'Andréa, Grégoire. "Apport de l'intelligence artificielle, de la protéomique et de la métabolomique dans la prise en charge des cancers thyroïdiens différenciés." Electronic Thesis or Diss., Université Côte d'Azur, 2024. http://www.theses.fr/2024COAZ6011.

Повний текст джерела
Анотація:
Les nodules thyroïdiens (NT) sont fréquents, et seuls 5-10% s'avèrent être cancéreux. La stratégie diagnostique qu'ils imposent est bien codifiée et permet de stratifier leur risque de malignité, mais ne permet toutefois pas de conclure sur la nature des NT dans 20-25% des cas, on parle alors de NT indéterminés (NTI). Cette situation conduit souvent à la réalisation d'une chirurgie diagnostique, retrouvant 66% de NT bénins. L'amélioration du diagnostic de ces NTI reste donc cruciale. Les cancers thyroïdiens différenciés (CDT) sont de très bon pronostic, grâce à des traitements reposant sur la chirurgie et la radiothérapie métabolique à l'iode 131, permettant de guérir la majorité des patients. Le suivi des CDT repose sur le dosage de la thyroglobuline (Tg) sérique, une molécule complexe. Toutefois, la Tg n'est pas spécifique des cellules cancéreuses thyroïdiennes, posant des défis d'interprétation. La découverte d'une forme de Tg plus spécifique aux cellules cancéreuses pourrait améliorer le suivi des CDT et servir d'outil diagnostic.Dans ce contexte, les objectifs de ma thèse ont été i) d'améliorer la prédiction du risque de malignité des NTI par l'utilisation d'algorithmes d'intelligence artificielle (IA) et d'une approche métabolomique, et ii) de mieux caractériser les modifications post-traductionnelles (MPT) de la Tg humaine afin de servir de base à l'identification d'une Tg spécifique des cellules cancéreuses thyroïdiennes, facilitant l'identification des récidives chez les patients traités pour un CDT. Pour ce faire, nous avons dans un premier temps comparé l'efficacité d'algorithmes d'IA pour prédire le risque de malignité des NTI à partir de données cliniques récoltées sur une cohorte rétrospective multicentrique de 1290 patients (1337 NT). L'utilisation d'un autoencodeur supervisé a obtenu les meilleurs scores de performance avec une accuracy de 85,19% (±1,5), une AUC de 82,99% (±1,73), et un F1 score de 84,02% (±1,66). Dans un deuxième travail, nous avons pu identifier une signature métabolomique sur des échantillons de cytoponction thyroïdienne par spectrométrie de masse en tandem couplée à la chromatographie liquide (LC-MS/MS), permettant de différencier les nodules bénins des nodules malins parmi les NTI. L'utilisation de l'autoencodeur supervisé sur cette signature métabolomique a permis d'atteindre des performances diagnostiques remarquables, avec une accuracy de 95,7% (0,842-1), une AUC de 94,5% (0,833-1) et un F1 score de 94,7% (0,842-1). En perspective, la validation prospective à grande échelle des résultats obtenus et l'adoption d'une approche hybride combinant données cliniques et métabolomiques (notamment sur des prélèvements moins invasifs qu'une cytoponction thyroïdienne) vont être débutés. Enfin, nous avons réalisé une cartographie exhaustive des MPT de la Tg humaine via une approche protéomique par nano LC-MS/MS pour mieux comprendre sa complexité. Cette étude a révélé un spectre plus large de sites de N-glycosylation, d'oxydation, et d'iodation que précédemment rapporté, fournissant une ressource précieuse pour les futures recherches visant à comprendre la modulation des MPT de la Tg et leur rôle. En perspective, l'identification des différences observables des MPT de la Tg entre cellules thyroïdiennes saines et cancéreuses pourrait permettre l'identification d'une Tg plus spécifique de ces dernières, facilitant l'identification des récidives chez les patients traités pour un CDT et offrant des innovations diagnostiques et thérapeutiques en oncologie thyroïdienne. Cette thèse ouvre ainsi la voie à de nouvelles stratégies diagnostiques et de suivi basées sur la métabolomique, la protéomique et l'intelligence artificielle dans le contexte des NT et CDT
Thyroid nodules (TN) are common, with only 5-10% being cancerous. The diagnostic strategy for TN is well-established, allowing stratification of their malignancy risk; however, it fails to determine the nature of TN in 20-25% of cases, known as indeterminate thyroid nodules (ITN). This often leads to diagnostic surgery, revealing benign nodules in 66% of cases. Improving the diagnosis of these ITN is therefore crucial. Differentiated thyroid cancers (DTC) have a very good prognosis, thanks to treatments involving surgery and radioactive iodine therapy, which cure the majority of patients. Follow-up of DTC relies on the measurement of serum thyroglobulin (Tg), a complex molecule. However, Tg is not specific to thyroid cancer cells, posing interpretation challenges. Discovering a form of Tg more specific to cancer cells could enhance DTC follow-up and serve as a diagnostic tool.In this context, the objectives of my thesis were: i) to improve the prediction of malignancy risk in NTI using artificial intelligence (AI) algorithms and a metabolomic approach, and ii) to better characterize the post-translational modifications (PTMs) of human Tg to serve as a basis for identifying a Tg specific to thyroid cancer cells, facilitating the identification of recurrences in patients treated for DTC. To achieve this, we first compared the efficacy of AI algorithms to predict the malignancy risk of NTI using clinical data collected from a retrospective multicentric cohort of 1290 patients (1337 TN). The use of a supervised autoencoder achieved the best performance scores with an accuracy of 85.19% (±1.5), an AUC of 82.99% (±1.73), and an F1 score of 84.02% (±1.66). In a second study, we identified a metabolomic signature from thyroid fine-needle aspiration (FNA) samples using tandem mass spectrometry coupled with liquid chromatography (LC-MS/MS), enabling the differentiation between benign and malignant nodules among ITN. The use of the supervised autoencoder on this metabolomic signature achieved remarkable diagnostic performance, with an accuracy of 95.7% (0.842-1), an AUC of 94.5% (0.833-1), and an F1 score of 94.7% (0.842-1). Prospectively, the large-scale validation of the obtained results and the adoption of a hybrid approach combining clinical and metabolomic data (especially from less invasive samples than thyroid FNA) are planned. Finally, we conducted an exhaustive mapping of the PTMs of human Tg using a proteomic approach by nano LC-MS/MS to better understand its complexity. This study revealed a broader spectrum of N-glycosylation, oxidation, and iodination sites than previously reported, providing a valuable resource for future research aimed at understanding the modulation and roles of Tg PTMs. Looking ahead, identifying observable differences in Tg PTMs between healthy and cancerous thyroid cells could lead to the identification of a Tg specific to the latter, facilitating the identification of recurrences in patients treated for DTC and offering diagnostic and therapeutic innovations in thyroid oncology. This thesis thus paves the way for new diagnostic and follow-up strategies based on metabolomics, proteomics, and artificial intelligence in the context of NT and DTC
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Lang, Brian. "Cancer staging for differentiated thyroid carcinoma." Click to view the E-thesis via HKUTO, 2006. http://sunzi.lib.hku.hk/hkuto/record/B36916134.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Mehrotra, Pallavi. "Molecular characteristics of differentiated thyroid cancer." Thesis, University of Newcastle upon Tyne, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.405074.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Chow, Sin-ming, and 周倩明. "Differentiated thyroid cancer in Hong Kong." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B41290847.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Lang, Brian, and 梁熊顯. "Cancer staging for differentiated thyroid carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B36916134.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Chow, Sin-ming. "Differentiated thyroid cancer in Hong Kong." Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/hkuto/record/B41290847.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Ciappuccini, Renaud. "Apport de l'imagerie fonctionnelle par TEMP/TDM et TEP/TDM dans la prise en charge des cancers différenciés de la thyroïde Incremental Value of a Dedicated Head and Neck Acquisition during 18F-FDG PET/CT in Patients with Differentiated Thyroid Cancer Full text links full-text provider logo Actions Favorites Share Page navigation Title & authors Abstract Conflict of interest statement Figures Similar articles Cited by References Related information LinkOut - more resources EJNMMI Res . 2018 Dec 3;8(1):104. doi: 10.1186/s13550-018-0461-x. Optimization of a dedicated protocol using a small-voxel PSF reconstruction for head-and-neck 18 FDG PET/CT imaging in differentiated thyroid cancer 78 Lymph node involvement in head-and-neck and thyroid cancers with digital PET/CT: the impact of ultra-high definition voxels and point-spread function Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome 133 18F-Fluorocholine PET/CT is a highly sensitive but poorly specific tool for identifying malignancy in thyroid nodules with indeterminate cytology: The Chocolate study PSMA expression in neovasculature of persistent/recurrent differentiated thyroid cancerin the neck: relationship with radioiodine uptake, 18Fluorodeoxyglucose avidity and outcome." Thesis, Normandie, 2020. http://www.theses.fr/2020NORMC424.

Повний текст джерела
Анотація:
L’imagerie scintigraphique des cancers thyroïdiens différenciés (CTD) présente la particularité d’utiliser deux radiopharmaceutiques, l’iode 131 (131I) et le 18-Fluorodésoxyglucose (18FDG). La fixation de ces traceurs dépend habituellement du degré de différenciation et de l’agressivité de la tumeur. L’objectif de ce travail était d’étudier l’apport de différents aspects techniques et d’instrumentation, à savoir l’imagerie hybride par TEMP/TDM et TEP/TDM, la point-spread function (PSF), la taille des voxels et la technologie TEP digitale, et d’explorer si d’autres traceurs TEP pouvaient présenter un intérêt. Le but de la première partie était d’étudier les performances de la TEP/TDM au 18FDG à l’étage cervical pour la détection de la maladie ganglionnaire. Une acquisition TEP/TDM dédiée a amélioré la détection de la maladie tumorale par rapport à l’acquisition classique. L’utilisation de la PSF a permis de détecter des tailles de lésions plus petites et la durée optimale de cette acquisition a été évaluée. Des reconstructions avec des tailles de voxels ultra-fines ont été réalisées sur TEP digitale pour étudier l’impact de la PSF et des voxels ultra-fins sur les données quantitatives. La seconde partie a porté sur l’imagerie 131I-TEMP/TDM et 18FDG-TEP/TDM, afin de quantifier le volume de la maladie persistante. Il a ainsi été montré que la masse tumorale était corrélée au risque post-opératoire et avait un impact sur la réponse au traitement. L’objectif de la troisième partie était d’étudier un autre traceur TEP, la 18-Fluorocholine (FCH), ainsi qu’un marqueur de la néovascularisation, l’antigène membranaire spécifique de la prostate (PSMA). Nos données suggèrent qu’un examen TEP à la FCH négatif au sein d’un nodule thyroïdien à cytologie indéterminée permettrait d’éliminer la malignité, et pourrait éviter des chirurgies inutiles. Par ailleurs, le marquage au PSMA évalué par immunohistochimie dans les néo-vaisseaux est associé à des facteurs de mauvais pronostic. D’autres études sont nécessaires pour confirmer l’intérêt éventuel des examens TEP à la FCH et au 68Ga-PSMA en oncologie thyroïdienne
Radioiodine (131I) and 18-Fluorodeoxyglucose (18FDG) are two radiopharmaceuticals used for scintigraphic imaging in differentiated thyroid cancers (DTC). Tumour uptake of each tracer depends on tumour differentiation and aggressiveness. Our goal was to further assess various technical aspects in DTC imaging workup, such as SPECT/CT and PET/CT, point-spread function (PSF), voxel size, digital PET, and to explore further other PET tracers. The aim of the first part was to assess the performance of 18FDG PET/CT for the detection of neck lymph node involvement. A dedicated PET/CT acquisition improved tumour detection compared to the whole-body acquisition. PSF reconstruction allowed detection of smaller cancer deposits and the optimal acquisition duration time was assessed. Using digital PET acquisitions, ultra-thin voxels reconstructions were performed. The impact of ultra-thin voxels and PSF on quantitative values was evaluated. The second part focused on 131I-SPECT/CT and 18FDG-PET/CT imaging, in an attempt to assess tumour burden of persistent disease. Tumor burden was correlated with the postoperative risk and affected the response to therapy. In the third part, another PET tracer, i.e. 18-Fluorocholine (FCH), and a marker of neovasculature, i.e. prostate-specific membrane antigen (PSMA), were studied. FCH PET/CT offered high negative predictive value to reliably exclude cancer in PET-negative nodules with indeterminate cytology and might prevent unnecessary surgeries. Also, PSMA expression assessed with immunohistochemistry was associated with poor prognosis factors. Further studies are needed to confirm new insights of FCH PET and 68Ga-PSMA PET in DTC
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Marcelino, Ana Sousa. "Targeting thyroid stimulating hormone receptors in radioiodine resistent de-differentiated thyroid cancer." Thesis, Queen Mary, University of London, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.576914.

Повний текст джерела
Анотація:
The most common type of thyroid cancer, differentiated thyroid cancer (DTC), is diagnosed by radioactive iodine whole body scanning (WBS) and treated with radiotherapy using iodine-13I C31 I). The success of this diagnosis/treatment approach relies on the relatively selective localisation of the sodium/iodide symporter (NIS) in cells of the thyroid gland. However, in some de-differentiated thyroid cancers, NIS expression is lost. This results in the inability of WBS to stage the disease and it also decreases the effectiveness of treatment with 131 I. A number of reports have shown that de-differentiated thyroid carcinomas, however, continue to express thyroid stimulating hormone receptor (TSHR). TSHR is, therefore, a potential target for the diagnosis and treatment of radioiodine resistant de-differentiated thyroid carcinoma. In this study an anti- TSHR mono clonal antibody (mAb9) and human recombinant TSH (rhTSH) were radio labelled and evaluated for their potential use in the diagnosis and treatment of radioiodine resistant thyroid cancer. A number of radiolabelling methods and quality control experiments were initially carried out to ensure high purity radiolabelled mAb9 and rhTSH were produced. In vitro studies were conducted to assess the binding affinity of 125I_mAb9, lllIn-mAb9 and 125I_rhTSH to the TSHR in thyroid cancer cell lines, TPC-I,FTC-133, and FRTL5, and in a TSHR transfected cell line, GPI. SPECT/CT aJimal studies were performed in mice to investigate whether 125I_mAb9, 111In-mAb9 and 125I_rhTSH bound to TSHR in the thyroid of mice in vivo. 125I_mAb9, 11lIn_mAb9 and 125I_rhTSH bound to GPI cells but did not bind specifically to the TSHR in FTC-133, TPC-I and FRTL5 cells as well as to the thyroid of normal mice in vivo. Radiolabelled mAb9 and radiolabelled rhTSH are therefore unlikely to be of use in the diagnosis and treatment of radioiodine resistant de-differentiated thyroid cancer.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Differentiated thyroid cancers"

1

Greene, Frederick L., and Andrzej L. Komorowski, eds. Clinical Approach to Well-differentiated Thyroid Cancers. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Mancino, Anne T., and Lawrence T. Kim, eds. Management of Differentiated Thyroid Cancer. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-54493-9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Roman, Sanziana A., Julie Ann Sosa, and Carmen C. Solórzano, eds. Management of Thyroid Nodules and Differentiated Thyroid Cancer. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43618-0.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Roman, Sanziana A., Wen T. Shen, and Julie Ann Sosa, eds. Controversies in Thyroid Nodules and Differentiated Thyroid Cancer. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-37135-6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Greene, Frederick L., and Andrzej L. Komorowski. Clinical Approach to Well-differentiated Thyroid Cancers. Springer, 2016.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Greene, Frederick L., and Andrzej L. Komorowski. Clinical Approach to Well-Differentiated Thyroid Cancers. Springer, 2015.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Greene, Frederick L., and Andrzej L. Komorowski. Clinical Approach to Well-differentiated Thyroid Cancers. Springer, 2015.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Mancino, Anne T., and Lawrence T. Kim. Management of Differentiated Thyroid Cancer. Springer International Publishing AG, 2017.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Mancino, Anne T., and Lawrence T. Kim. Management of Differentiated Thyroid Cancer. Springer International Publishing AG, 2018.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Roman, Sanziana A., Julie Ann Sosa, and Carmen C. Solórzano. Management of Thyroid Nodules and Differentiated Thyroid Cancer: A Practical Guide. Springer, 2018.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Differentiated thyroid cancers"

1

D'cruz, Anil, and Richa Vaish. "Surgical Management of Differentiated Thyroid Cancers." In Thyroid Surgery, 105–11. First edition. | Boca Raton : CRC Press, 2020.: CRC Press, 2020. http://dx.doi.org/10.1201/9780429086076-14.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Ryś, Janusz, and Joanna Wysocka. "Pathology of Differentiated Thyroid Cancers." In Clinical Approach to Well-differentiated Thyroid Cancers, 5–22. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Wysocki, Wojciech M., Andrzej L. Komorowski, and Frederick L. Greene. "Staging of Differentiated Thyroid Cancer." In Clinical Approach to Well-differentiated Thyroid Cancers, 41–44. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Gwyther, Stephen J. "Imaging in Thyroid Cancer." In Clinical Approach to Well-differentiated Thyroid Cancers, 27–39. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Burnison, C. Michele. "External Beam Radiation Therapy in the Treatment of Differentiated Thyroid Cancers." In Thyroid Cancer, 271–99. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-0875-8_14.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Barczyński, Marcin. "Surgical Treatment of Thyroid Cancer." In Clinical Approach to Well-differentiated Thyroid Cancers, 55–77. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Iacconi, Pietro, and Carmine De Bartolomeis. "Postoperative Complications in Thyroid Surgery." In Clinical Approach to Well-differentiated Thyroid Cancers, 115–24. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_12.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Yip, Linwah, and Sally E. Carty. "Differentiated Thyroid Cancers of Follicular Cell Origin." In Endocrine Neoplasia, 35–56. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-1-4419-0857-5_3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Komorowski, Artur, and Andrzej L. Komorowski. "Clinical Evaluation of the Thyroid Gland." In Clinical Approach to Well-differentiated Thyroid Cancers, 23–26. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Gal, Istvan. "Minimally Invasive Approach to the Thyroid." In Clinical Approach to Well-differentiated Thyroid Cancers, 79–91. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Differentiated thyroid cancers"

1

Dogra, Akash, Srishti Sharma, Daksh Rawat, Harshit Narang, Satvik Vats, and Vikrant Sharma. "Using XGBoost for Risk Stratification in Differentiated Thyroid Cancer Recurrence Prediction." In 2024 IEEE 3rd World Conference on Applied Intelligence and Computing (AIC), 472–77. IEEE, 2024. http://dx.doi.org/10.1109/aic61668.2024.10731128.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

AMIT, MORAN, shorook Na’ara, Tomer Charas, and Ziv gil. "Abstract 2879: PIGU modulates radioactive iodine uptake in differentiated thyroid cancers." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2879.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Stephen, Josena K., Kang Mei Chen, Jason Merritt, Indrani Datta, Dhananjay Chitale, George Divine, and Maria J. Worsham. "Abstract 3361: Methylome differences in differentiated thyroid cancers and benign adenomas." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3361.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Copland, John, Kendall Schick, Justyna Gleba, Truc Huynh, James Miller, Erin MIller, Aylin Alasonyalilar Demirer, et al. "324 Sensitizing poorly differentiated thyroid cancers to TSHR-CART cell therapy with MEK inhibitors." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0324.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Begić, Amela, and Elma Kučukalić-Selimović. "RADIOIODINE THERAPY OF DIFFERENTIATED THYROID CANCER – PRINCIPLES AND PRACTICE." In Tumori štitnjače u kliničkoj praksi. Akademija nauka i umjetnosti Bosne i Hercegovine, 2016. http://dx.doi.org/10.5644/pi2016.167.04.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

K, Bharath, and A. Sai Sabitha. "Predicting Recurrence in Differentiated Thyroid Cancer: A Machine Learning Approach." In 2024 International Conference on Advances in Data Engineering and Intelligent Computing Systems (ADICS). IEEE, 2024. http://dx.doi.org/10.1109/adics58448.2024.10533649.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Allauca, Erika, Vilma Yanchapanta, and Javier Toasa Tapia. "Calculation of accumulated absorbed radiation dose in patients with differentiated thyroid cancer." In PROCEEDINGS OF THE 2ND INTERNATIONAL CONGRESS ON PHYSICS ESPOCH (ICPE-2017). Author(s), 2018. http://dx.doi.org/10.1063/1.5050353.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Park, Gahee, Tae Hyuk Kim, Hae-Ock Lee, Jung Ah Lim, Jae-Kyung Won, Hye Sook Min, Kyu Eun Lee, Do Joon Park, Young Joo Park, and Woong-Yang Park. "Abstract 2134: Standard immunohistochemistry efficiently screens for ALK rearrangements in differentiated thyroid cancer." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2134.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Bouyoucef, Salah, Abdelkrim Talbi, Dalila Mouas, Assia Amimour, Skander Rahabi, and Amel Khelifa. "Crucial Role of Iodine 131 in the Management of Bone Metastasis of Differentiated Thyroid Cancer." In Abstracts for the 18th International Conference on Radiopharmaceutical Therapy (ICRT). Thieme Medical and Scientific Publishers Pvt. Ltd., 2023. http://dx.doi.org/10.1055/s-0043-1769958.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Yartey, Miriam N. Y., Clement Korsah, and Alfred O. Ankrah. "A Clinical and Ethical Dilemma during Radioiodine Therapy for Well-Differentiated Thyroid Cancer—A Case Report." In Abstracts for the 18th International Conference on Radiopharmaceutical Therapy (ICRT). Thieme Medical and Scientific Publishers Pvt. Ltd., 2023. http://dx.doi.org/10.1055/s-0043-1769988.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Differentiated thyroid cancers"

1

Alessa, Mohammed, Tayba Wahedi, Jumanah Alsairafi, Nouf Almatrafi, Wisal Shuaib, Johara Alnafie, Fatimah Alzubaidi, and Soha Elmorsy. Prevalence of Thyroid cancer in Saudi Arabis: Systematic review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0088.

Повний текст джерела
Анотація:
Review question / Objective: What is the prevalence of Thyroid cancer among population in kingdom of Saudi Arabia?. The aim of this systematic review is to scrutinize the prevalence of thyroid cancer (TC) in Saudi Arabia and assess the relative frequency of subgroups related to types of thyroid cancer, age, and gender. Condition being studied: Thyroid cancer is an abnormal growth of cells that starts in the thyroid gland. There is four types of differentiated thyroid cancer, three of these cancer develop from the follicular cells, the papillary thyroid cancer, follicular thyroid cancer, Hürthle cell carcinoma, and one rare type develops from the thyroid’s C cells called medullary thyroid cancer. There is one undifferentiated thyroid cancer called anaplastic thyroid cancer.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Zhao, Hao, Chunhao Liu, Yanlong Li, and Xiaoyi Li. Prognostic factors for survival in differentiated thyroid cancer with pulmonary metastases: a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0026.

Повний текст джерела
Анотація:
Pulmonary metastasis (PM) is the most common form of distance metastasis in differentiated thyroid cancer (DTC), which has a poor prognosis. However, the prognostic risk factors are not yet well identified and analyzed. This systematic review and meta-analysis aims to fill this blank though identifying and discussing survival prognostic risk factors systematically for DTC patients with PM. Pulmonary metastasis (PM) is the most common form of distance metastasis in differentiated thyroid cancer (DTC), which has a poor prognosis. However, the prognostic risk factors are not yet well identified and analyzed. This systematic review and metastases aims to fill this blank though identifying and discussing survival prognostic risk factors systematically of DTC patients with PM. Condition being studied: differentiated thyroid cancer with pulmonary metastases.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Wang, Yizhen, Zhicheng Jin, Fang Zhang, and Yangting Mao. The efficacy and influencing factors of radioactive iodine in the treatment of patients with lung metastasis of differentiated thyroid cancer: a meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0093.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Differentiated thyroid cancers" для конкретних типів джерел:
Статті в журналах Дисертації
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії